Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A multicentre phase I/II trial to investigate the efficacy, biological activity, safety and tolerability of IPH 1101 and low dose interleukin-2 in combination with rituximab [Mabthera/Rituxan] in patients with follicular non-Hodgkin's lymphoma relapsing after at least one prior rituximab-containing course of treatment.

Trial Profile

A multicentre phase I/II trial to investigate the efficacy, biological activity, safety and tolerability of IPH 1101 and low dose interleukin-2 in combination with rituximab [Mabthera/Rituxan] in patients with follicular non-Hodgkin's lymphoma relapsing after at least one prior rituximab-containing course of treatment.

Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 02 Jun 2011

At a glance

  • Drugs IPH 1101 (Primary) ; Aldesleukin; Rituximab
  • Indications Follicular lymphoma
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Innate Pharma
  • Most Recent Events

    • 31 Aug 2018 Biomarkers information updated
    • 14 Jun 2010 Status changed from recruiting to active, no longer recruiting.
    • 14 Jun 2010 Final data of this trial has been presented at the Annual European Hematology Association (EHA) Meeting 2010, according to an Innate Pharma media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top